The damage inflicted by extends far beyond financial loss.
The solution is multifaceted:
The scientific community is cautiously optimistic. In 2023, the European Medicines Agency (EMA) granted Yara Mateni "orphan drug" status for the treatment of chronic fatigue syndrome (myalgic encephalomyelitis), allowing accelerated research pathways. Two Phase II clinical trials are currently underway investigating its efficacy in long-COVID recovery and post-chemotherapy immune restoration. yara mateni